NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/altimmune-inc-lawsuit-subm ...

诉讼背景 - 律所Levi & Korsinsky代表Biohaven Ltd投资者提起集体诉讼 诉讼针对2023年3月24日至2025年5月14日期间因证券欺诈遭受损失的投资者 [1] 指控内容 - 公司被指控夸大治疗脊髓小脑共济失调(SCA)的药物troriluzole的监管前景和提交数据的充分性 [2] - 公司被指控夸大治疗双相情感障碍的药物BHV-7000的疗效和临床前景 [2] - 上述问题曝光后可能对公司业务和财务状况产生重大负面影响 [2] - 被告的公开陈述在所有相关时间均存在重大虚假和误导性 [2] 诉讼程序 - 投资者需在2025年9月12日前申请成为首席原告 [3] - 集体成员可能无需支付自付费用即可获得补偿 [3] 律所资质 - Levi & Korsinsky过去20年为受损股东追回数亿美元资金 [4] - 该律所在美国证券诉讼律师事务所中连续七年跻身ISS证券集体诉讼服务Top 50报告 [4] - 拥有70多名员工组成的团队 在复杂证券诉讼方面具有丰富经验 [4]

诉讼核心信息 - Levi & Korsinsky律所通知Alto Neuroscience公司投资者有关一项证券集体诉讼 [1] - 诉讼旨在为因涉嫌证券欺诈而遭受损失的投资者挽回损失 [2] 诉讼类别与时间范围 - 集体诉讼类别涵盖通过公司2024年2月2日左右进行的首次公开发行相关发行文件购买或收购Alto普通股的个人和实体 [2] - 诉讼类别同时涵盖在2024年2月2日至2024年10月22日期间购买Alto证券的所有个人和实体 [2] 指控内容 - 指控称被告作出虚假陈述和/或隐瞒了公司产品管线ALTO-100在治疗重度抑郁症方面的效果不如被告向投资者宣称的那样有效 [3] - 指控认为ALTO-100的临床、监管和商业前景因此被夸大 [3] - 指控指出公司的业务和/或财务前景因此被夸大 [3] - 指控结论是公司在相关时间内的公开声明存在重大虚假和误导性 [3]

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/ ...

公司调查事件 - Frank R Cruz律师事务所宣布对Quanex Building Products Corporation展开调查 涉及公司可能违反联邦证券法的行为 [1] - 调查针对因投资Quanex遭受损失的投资者 可能通过索赔追回损失 [1] - 调查直接关联2025年9月4日公司发布的信息 [1]

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 12, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Biohaven Ltd. ("Biohaven†or the "Company†) (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO LOST MONEY ON BIOHAVEN LTD. (BHVN), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAU. ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or “the Company”) (NASDAQ: LNTH) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lant ...

文章核心观点 - 一家律师事务所宣布对Nutex Health Inc提起集体诉讼 指控该公司在特定期间内发布了重大虚假和/或误导性陈述 并未能披露重要事实 导致其股价被人为抬高 [1] 针对Nutex Health Inc的指控 - 指控称 Nutex Health的第三方IDR供应商HaloMD通过一项欺诈保险公司的协同计划为其获取有利的仲裁结果 [1] - 由于该等收入源于欺诈行为 公司通过HaloMD在IDR过程中产生的收入是不可持续的 [1] - 公司夸大了其对财务报告内部控制重大弱点的整改程度和/或整改能力 [1] - 公司无法有效核算其部分基于股权的薪酬义务 错误地将其计算为权益而非负债 [1] - 上述问题增加了公司无法及时向美国证券交易委员会提交某些财务报告的风险 [1] - 因此 公司的业务和/或财务前景被夸大 其公开陈述在相关时间均存在重大虚假和误导性 [1] 集体诉讼程序信息 - 集体诉讼期定义为2024年8月8日至2025年8月14日 [1] - 股东登记参与集体诉讼的截止日期为2025年10月21日 [2] - 股东在登记后将加入投资组合监控软件 以获取案件进展状态更新 [2]

Accessibility StatementSkip Navigation NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=166350&from= ...

NEW YORK, Sept. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). Shareholders who purchased shares of UNCY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/unicycive-therapeutics-inc-loss-submission-form/?id=166344&from=4 CLASS ...